ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ PHẪU THUẬT VÀ HOÁ TRỊ BỔ TRỢ PACLITAXEL-CARBOPLATIN TRÊN BỆNH NHÂN UTBM BUỒNG TRỨNG GIAI ĐOẠN III TẠI BỆNH VIỆN K

Abstract

Objects: Evaluation of the efficacy and toxicity of paclitaxel-carboplatin adjuvant chemotherapy after primary debulking surgery (PDS) in patients with stage III epithelial ovarian cancer in the Vietnamese population. Methods: Patients with epithelial ovarian cancer stage III with eligibility criteria undergone the primary debulking surgery and the adjuvant chemotherapy regimens paclitaxel plus carboplatin at the K hospital from January 2015 to December 2019. Results: 105 eligible patients with stage III epithelial ovarian cancer were collected and analyzed. Characteristics of the study population: stage IIIC accounted for the majority with 65.7%, the predominant histopathologic subtype was serous carcinoma of about 85%. Median overall survival was 46 months (95% CI = 39.2 to 52.8 months), and median progression-free survival was 18 months. (95% CI = 14.1 to 21.9 months). There was a significant correlation between the optimal cytoreductive surgery surgery rate and the median survival time with p < 0.001. Conclusions: Primary cytoreductive surgery combined with adjuvant chemotherapy Paclitaxel-Carboplatin proved effective in patients with stage III ovarian cancer. Residual disease after surgery is an important prognostic factor, therefore, efforts should be made to achieve optimal cytoreductive surgery, especially in patients with large initial tumor burden.